BI-891065
- Generic Name
- BI-891065
A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT04138823
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Phase 1
Terminated
- Conditions
- NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT03166631
- Locations
- 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath